On a per­son­al mis­sion for his daugh­ter, Paul Bres­ge launch­es an­oth­er eye dis­ease biotech with $100M for Ray Ther­a­peu­tics

As Paul Bres­ge’s for­mer oph­thal­mol­o­gy biotech gears up for a Phase III cell ther­a­py study in re­tini­tis pig­men­tosa, he’s out with an­oth­er drug de­vel­op­ment start­up, this time tack­ling the rare, de­gen­er­a­tive reti­nal dis­ease with a gene ther­a­py ex­pect­ed to en­ter a Phase I tri­al next year.

To get there, and launch the glob­al clin­i­cal tri­al of RTx-015, Ray Ther­a­peu­tics has raised $100 mil­lion in Se­ries A funds that will al­so bankroll an ex­pan­sion in­to a rare, ge­net­ic eye dis­ease known as Star­gardt’s as well as ge­o­graph­ic at­ro­phy, a lead­ing cause of blind­ness for which there is now a treat­ment, as of Feb­ru­ary’s Apel­lis Phar­ma­ceu­ti­cals ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER